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Abstract
The sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) is under the control of a closely associated SR protein named phospholamban 
(PLN). Dephosphorylated PLN inhibits the SR Ca2+ pump, whereas phosphorylation of PLN, at either Ser16 by PKA or Thr17 by calmodulin­
dependent protein kinase II (CaMKII), reverses this inhibition, thus increasing SERCA2a activity and the rate of Ca2+ uptake by the SR. This 
would in turn lead to an increase in the velocity of relaxation, SR Ca2+ load, and myocardial contractility. Thus, PLN is a major determinant 
of cardiac contractility and relaxation. Although in the intact heart, h-adrenoceptor stimulation results in phosphorylation of PLN at both 
Ser16 and Thr17 residues, the role of Thr17 site has long remained equivocal. In this review, we attempt to highlight the signaling cascade and 
the physiological relevance of the phosphorylation of this residue in the heart under both physiological and pathological situations. 
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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1. Introduction
During cardiac action potential, Ca2+ enters the cell 
through voltage-dependent Ca2+ channels (L-type Ca2+ 
channels) and subsequently binds and activates the ryano­
dine receptors (RyR2) on the sarcoplasmic reticulum (SR), to 
trigger further Ca2+ release. This process, termed Ca2+- 
induced-Ca2+-release [1], amplifies and coordinates the Ca2+ 
signal, which, by interacting with myofilament proteins, 
produces contraction. To allow for muscle relaxation 
between contractions, cytosolic Ca2+ must be decreased 
rapidly. This is mainly accomplished by the SR Ca2+-ATPase 
(SERCA2a), which mediates Ca2+ uptake into the SR, and in 
less proportion by the Na+/Ca2+ exchanger (NCX), which 
removes Ca2+ from the extracellular space [2].
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The activity of SERCA2a is under the control of a closely 
associated SR protein, named phospholamban (PLN) [3]. 
PLN is a 52 amino acid phosphoprotein, which, in the 
dephosphorylated form, decreases the apparent Ca2+-affinity 
of SERCA2a [4]. The use of gene knockout and transgenic 
mouse models, in which the expression levels of PLN has 
been ablated, reduced or increased, constituted a crucial step 
in the recognition of the role of PLN in the regulation of 
myocardial contractility and relaxation [5 –9]. Ablation of 
PLN produced an enhanced contractility and relaxation. This 
hypercontractile function of PLN-deficient hearts was 
associated with increases in the apparent affinity of SER- 
CA2a for Ca2+ and in the intraluminal SR Ca2+ content [5]. In 
contrast, overexpression of PLN was associated with a 
decreased apparent affinity of SERCA2a for Ca2+ and 
depressed cardiac contractile performance [8]. PLN-hetero- 
zygous hearts, expressing reduced protein levels of PLN, 
further support that the ratio PLN / SERCA2a plays a 
prominent role in regulating SR function and contractility [9].
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In addition to the relationship of PLN/SERCA2a, 
myocardial contractility and relaxation are also dependent 
on the degree of PLN phosphorylation. In vitro experiments 
have shown that PLN can be phosphorylated at three distinct 
sites: Ser16 by cAMP- and cGMP-dependent protein kinases 
(PKA and PKG, respectively), Thr17 by Ca2+ – calmodulin­
dependent protein kinase II (CaMKII), and Ser2 *10 by protein 
kinase C (PKC) [10 –13]. Phosphorylation of these sites 
reverses the inhibition of PLN upon SERCA2a, thus 
increasing the affinity of the enzyme for Ca2+ and the rate 
of SR Ca2+ uptake. Experimental evidence indicated that 
phosphorylation of Ser10 by PKC is not physiologically 
relevant [14]. Phosphorylation of Ser16 by PKG seems to 
play a role in the modulation of smooth muscle contraction 
[15] and has been also associated with a positive inotropic 
and lusitropic effect in mammalian heart [16]. Finally, 
phosphorylation of PLN by PKA and CaMKII pathways 
(Ser16 and Thr17 residues, respectively), is the main mediator 
of the positive inotropic and relaxant effect of h-adrenergic 
stimulation in cardiac muscle [17 – 27]. The increase in 
SERCA2a activity and Ca2+ uptake rate produced by these 
phosphorylations would lead to an increase in the velocity of 
relaxation, SR Ca2+ load and, as a consequence, SR Ca2+ 
release and myocardial contractility [17,18,20– 27]. The 
status of phosphorylation of PLN is also dependent on the 
activity of the type 1 phosphatase (PP1), the major SR- 
phosphatase that specifically dephosphorylates PLN [28]. 
The activity of PP1 is also under the control of different 
kinases and phosphatases. As will be discussed later, this 
phosphatase regulatory cascade, frequently overlooked when 
considering the regulation of PLN phosphorylation sites, is 
crucial in determining the status of PLN phosphorylation.
2. Phosphorylation of Thr17 of PLN under physiological
conditions
2.1. b-Adrenergic stimulation
2.1.1. PLN vs. other regulatory proteins
It is well established that h-adrenergic stimulation
phosphorylates several proteins in the cardiac myocytes,
among which are PLN and the RyR2 at the SR level, the L-
type Ca2+ channels, the NCX and phospholemman at the
sarcolemma, and troponin I (TnI), myosin-binding protein C 
and myosin light chain at the level of the myofibrils [2,17 – 
27]. Different studies indicated a fundamental role of PLN 
phosphorylation in the contractile and relaxant effects of h- 
adrenergic agents [17,18,20 – 27]. It was further demonstra­
ted that PLN phosphorylation is predominant in determining 
the mechanical effects of h-agonists vs. the phosphorylation 
of other proteins, also involved in the excitation – contrac­
tion-coupling. Two different experimental approaches are
In this article, we will particularly discuss the role of 
Thr17 phosphorylation of PLN under physiological and 
pathological processes.
particularly eloquent: 1. Dialysis of ventricular myocytes 
with a monoclonal antibody against PLN virtually sup­
pressed the mechanical effects of the h-agonists [29]; 2. 
Studies in different cardiac preparations from PLN-deficient 
mice indicated a significant attenuation of the inotropic and 
lusitropic effects of isoproterenol, compared with wild type 
preparations [5]. The effects of h-adrenergic stimulation 
appeared also greatly attenuated in in vivo echocardio­
graphic studies in PLN-ablated hearts [6]. This experimental 
evidence indicated that PLN is a major mediator of the h- 
adrenergic response in the mammalian heart. However, a 
role of other proteins different from PLN could not be 
excluded. In particular, recent experiments reconfirmed a 
previously questioned role of TnI phosphorylation in the 
relaxant effect of h-agonists [30].
2.1.2. Dual site PLN phosphorylation
Wegener et al. [19] first localized the amino acid residues 
of PLN phosphorylated in the intact heart in response to h- 
adrenoceptor stimulation, by using monoclonal antibody 
affinity purification of the 32P-labeled protein from perfused 
hearts, followed by phosphoaminoacid analysis and protein 
sequencing. These experiments showed that there were only 
two sites phosphorylated during h-adrenergic stimulation, 
Ser16 and Thr17, indicating that under these conditions, PKA 
and CaMKII pathways were phosphorylating PLN. More­
over, phosphorylation at Ser16 precedes that at Thr17, 
although at steady state, both sites were phosphorylated in 
approximately equimolar amounts [19]. Isoproterenol- 
induced phosphorylation of PLN by PKA and CaMKII 
activation was also observed by using different techniques, 
like back phosphorylation, 32P incorporation into PLN and 
more recently, specific immunodetection of PLN phosphor­
ylation sites (see below) [18,21 – 27]. All these studies 
indicated that dual phosphorylation of PLN does occur in 
vivo as it was the case of in vitro experiments (Fig. 1).
2.1.3. Independence and interdependence of PLN phosphory­
lation pathways. Functional role of Thr17 phosphorylation
Although in vitro studies indicate that PKA and CaMKII 
phosphorylations are independent of each other [31], earlier 
attempts to phosphorylate PLN by CaMKII in the intact heart 
had systematically failed, unless cAMP levels within the cell 
increase [17,18,22,32]. These findings suggested an inter­
action between PLN phosphorylation pathways. The avail­
ability of transgenic models, expressing either PLN-wild 
type (PLN-WT), the Ser16YAla mutant PLN (PLN-S16A) 
or the Thr17YAla mutant PLN (PLN-T17A) in the cardiac 
compartment of the PLN knock out mice (PLN-KO), and of 
phosphorylation site-specific antibodies to PLN, which 
precisely discriminate between phosphorylated Ser16 and 
Thr17 phosphorylation sites, allowed a more complete 
comprehension of the independence and/or interdependence, 
as well as of the relative functional role of dual site PLN 
phosphorylation in the intact heart. Experiments in trans­
genic mice, expressing either PLN-WT or PLN-S16A,
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Fig. 1. Cascade of events leading to phosphorylation of PLN during h-adernergic stimulation. Binding of a h -agonist to its receptor activates the heterotrimeric 
G protein, which through the dissociation of its a s subunit enhances adenylate cyclase (AC) activity. AC catalyzes cAMP formation, which binds to the 
regulatory subunits of PKA (R), causing the activation of the catalytic subunit C. The C subunit phosphorylates L-type Ca2+ channel, increasing the Ca2+ 
influx, Ser16 residue of PLN and PP1. PP1 is inhibited by PKA, acidosis or by the phosphatase inhibitor, okadaic acid (OA). The increase in intracellular Ca2+ 
causes the activation of CaMKII, a multimeric protein that undergoes autophosphorylation, a process that allows the enzyme to retain enzymatic activity in the 
absence of Ca2+. This autophosphorylation state is also controlled by PP1. CaMKII in turn phosphorylates PLN at the Thr17 residue.
demonstrated that the phosphorylation of Ser16 of PLN is a 
prerequisite for the phosphorylation of Thr17 [33], in line 
with earlier findings which indicated the dependence of the 
phosphorylation of Thr17 on intracellular cAMP levels 
[18,22,32]. Experiments in PLN-T17A hearts further 
showed that Ser16 can be phosphorylated independently of 
Thr17 in vivo and that phosphorylation of Ser16 was 
sufficient for mediating the maximal cardiac responses to 
h-adrenergic stimulation [34]. These experiments suggested 
a predominant role of the phosphorylation of Ser16 over that 
of Thr17, in the mechanical effect produced by h-adrenergic 
stimulation. The combination of phosphorylation site-spe­
cific antibodies with quantification of 32P incorporation into 
PLN further helped to clarify the relative role of Ser16 and 
Thr17 phosphorylation [23,27]. Perfusion with different 
isoproterenol concentrations in the presence of extremely 
low extracellular Ca2+ plus nifedipine, to avoid Ca2+ entry to 
the cell, decreased 32P incorporation into PLN at the highest 
but not at the lowest levels of h-adrenergic stimulation. 
These results suggested that there was no contribution of the 
CaMKII pathways to the total PLN phosphorylation at the 
lowest isoproterenol concentrations [22,27]. Immunodetec­
tion of site-specific phosphorylated PLN fully confirmed this 
suggestion, further indicating that the phosphorylation of 
Thr17 accounted for approximately 50% of the total PLN 
phosphorylation at the highest isoproterenol concentrations 
(^ 10 nM). This CaMKII-induced phosphorylation was 
closely associated with an increase in the relaxant effect of 
h-agonists [27]. In line with these findings, Kuschel et al. 
[25] and Bartel et al. [26], demonstrated that the dose – 
response curve of Thr17 phosphorylation to isoproterenol 
was shifted to the right, compared to that of Ser16 
phosphorylation, clearly indicating that Ser16 was the only 
phosphorylated site at the lowest isoproterenol concentra­
tions. The lack of contribution of Thr17 to the total PLN 
phosphorylation, at the lowest isoproterenol concentrations, 
may be attributed to the modest increase in PKA activity 
produced by the low h-adrenergic stimulation, which would 
produce only a small increase in intracellular Ca2+, not 
enough to activate CaMKII and phosphorylate Thr17 site. As 
will be discussed below, the modest increase in PKA activity 
would also fail to significantly inhibit the phosphatases that 
dephosphorylate PLN, further favoring the dephosphory­
lated state of Thr17 residue (Fig. 1).
A similar modest or null contribution of Thr17 phosphor­
ylation to the total PLN phosphorylation evoked by h- 
adrenergic agents occurred, even at the highest isoproterenol 
concentrations, when the drug was administrated under 
conditions that either preclude or produce only a moderate 
increase in intracellular Ca2+ or that inhibited CaMKII 
activity, as was the case of the experiments in which 
isoproterenol was administrated at low external Ca2+ and the 
presence of nifedipine, or in the presence of ryanodine or 
thapsigargin to block the function of SR and SERCA2a, 
respectively, or with the CaMKII inhibitor KN-93. In all 
these cases, Ser16 was the only PLN site showing an 
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increase in phosphorylation [23,26]. These results provide 
an explanation for the low level of Thr17 phosphorylation 
observed with maximal isoproterenol concentrations in adult 
rat myocytes by Calaghan et al. [24]. In these experiments, 
the contribution of Thr17 to the total PLN phosphorylation 
was much lower than that observed in isolated rat hearts 
labeled with 32P [23,27]. The reason for this discrepancy 
might lay in the lower extracellular Ca2+ used in the 
experiments in isolated myocytes [24], compared with that 
used in the perfused rat heart (1.0 vs. 1.34 mM). This 
difference, although small, is not negligible, since it is 
sufficient to evoke a significant increase in contractility in 
isolated rat myocytes [35]. These experimental conditions 
may lead to the erroneous conclusion that the Thr17 site is 
poorly phosphorylated and not important under h-adrener- 
gic stimulation. Similarly, the failure to find PLN phosphor­
ylation in transgenic mice in which Ser16 site was mutated to 
Ala must be attributed to the fact that the lack of 
phosphorylation of the Ser16 site precludes the increase in 
intracellular Ca2+ necessary to phosphorylate Thr17 [33].
Taken together, these findings demonstrated the additive 
nature of PKA and CaMKII pathways of PLN phosphor­
ylation, in agreement with the in vitro results [31]. In 
addition, they indicated that: a) in the absence of a 
phosphorylatable Thr17 site, Ser16 is sufficient for mediating 
the maximal cardiac responses to h-adrenergic stimulation 
[34]; b) when both sites are present, they both equally 
contribute to the total PLN phosphorylation at the highest 
levels of h-adrenergic stimulation [23]; c) at low isoproter­
enol concentrations (^ 3 nM), the increase in PLN 
phosphorylation (and the relaxant effect of isoproterenol) 
is exclusively determined by the increase in the phosphor­
ylation of Ser16 residue [23,25 –27].
2.2. Phosphorylation of Thr17 of PLN in the absence of 
b-adrenergic stimulation
The observation that CaMKII-dependent PLN phosphor­
ylation can only occur in the presence of h-adrenergic 
stimulation, i.e. when the cAMP levels within the cell and 
PKA activity increase [17,18,20 – 27,32], was in sharp 
contrast with the independence of both pathways of PLN 
phosphorylation, described in vitro [31]. A clue for under­
standing this apparent discrepancy was given by experi­
ments in which the activation of the CaMKII pathway and 
the phosphorylation of Thr17 residue were studied in the 
presence of the phosphatase inhibitor, okadaic acid. Under 
these conditions, the increase in contractility (intracellular 
Ca2+), produced by increasing extracellular Ca2+, evoked a 
significant increase in Thr17 phosphorylation associated 
with a relaxant effect, in the absence of any significant 
increase in cAMP levels and in the phosphorylation of Ser16 
of PLN [23]. These results indicate that Thr17 residue can be 
phosphorylated independently of Ser16 phosphorylation, as 
was described in vitro. Thus, the nature of the interaction 
between PKA and CaMKII cascades lies in a basic 
mechanism underlying any phosphorylation process, i.e., 
the relative degree of kinases and phosphatases activity. It is 
important to note in this context that PP1 also dephosphor­
ylates CaMKII [36]. Thus, inhibition of PP1 would 
contribute to sustained phosphorylation of CaMKII, which 
allows the enzyme to maintain its activity, independently of 
the Ca2+ level (Fig. 1).
Taken together the results indicate that phosphorylation of 
Thr17 residue could be detected in intact preparations in the 
following situations (Fig. 1): a) in the presence of high 
extracellular Ca2+ (to activate CaMKII) and under conditions 
that inhibit PP1; b) at high intracellular cAMP, which by 
activation of PKA, is able to account for both effects, i.e. the 
increase in intracellular Ca2+ and the inhibition of PP1 [37].
2.2.1. FDAR and Thr17 phosphorylation
A still controversial issue is the role of Thr17 phosphor­
ylation on the frequency-dependent acceleration of relaxa­
tion (FDAR) [2]. Frequency is one of the fundamental 
physiological modulators of myocardial performance. In 
most of the species, the increase in contraction frequency 
produces an increase in contractility (positive treppe 
phenomenon). However, rats and mice as well as the failing 
myocardium commonly show a flat or even negative force – 
frequency relationship. Regardless of whether the force – 
frequency relationship is positive or negative, an increase in 
stimulation frequency is always associated with a relaxant 
effect, the mechanism of which is unclear. De Konink and 
Schulman elegantly showed that CaMKII can decode the 
frequency of Ca2+ spikes into distinct amounts of kinase 
activity [38]. Thus, the increase in contraction frequency 
would produce a sustained increase in CaMKII, which 
might lead to the phosphorylation of Thr17 of PLN, 
without the necessity of phosphatase inhibition. In agree­
ment with this attractive hypothesis, Hagemann et al. did 
show an increase in the phosphorylation of Thr17 with the 
increase in stimulation frequency and a good correlation 
between this increase and FDAR in rat myocytes [39]. 
Moreover, experiments in transgenic mice demonstrated 
that myocytes from Thr17YAla mutant PLN mice have a 
significantly diminished FDAR with respect to myocytes 
from Ser16YAla mutant PLN and WT mice [40]. Whereas 
these results indicate that Thr17 is indeed involved in 
FDAR, experiments by DeSantiago et al. in PLN-KO mice 
indicated that FDAR does not require PLN [41]. Moreover, 
although experiments in cat myocytes did show a good 
correlation between the phosphorylation of Thr17 and 
FDAR, they further demonstrated that FDAR actually 
preceded the increase in the phosphorylation of Thr17 
evoked by increasing frequency [42]. Finally, the stim­
ulation-frequency induced increase in Thr17 site could not 
be detected in the perfused heart, in spite of the presence 
of FDAR [42].
Overall, it is difficult to reconcile the outcomes of the 
different experimental approaches used to study the role of 
the phosphorylation of Thr17 of PLN on FDAR, and the 
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underlying mechanism of this phenomenon still remains an 
open question.
2.3. Interaction of PKA and Ca2+ signaling pathways at the 
level of PP1
PP1 is a serine/threonine phosphatase composed of two 
subunits, PP1GM and PP1C. PP1GM, the regulatory subunit, 
is responsible for the localization of the catalytic subunit, 
PP1C, to the SR. The binding of PP1C to PP1GM enhances 
the activity of the phosphatase towards its substrates, like 
PLN. Fig. 2 depicts some central players of the PP1 
regulatory cascade. PKA phosphorylates PP1GM on Ser48 
and Ser67 residues, both in vitro and in vivo [43,37]. 
Phosphorylation of Ser67 site triggers dissociation of PP1C 
from PP1GM, thereby inactivating its phosphatase activity 
[43]. In contrast, the phosphorylation of Ser48 increases the 
activity of PP1C, but this activation is overridden by the 
phosphorylation of Ser67 and the consequent dissociation of 
PP1C from PP1GM [44]. Thus, the net result of PKA 
phosphorylation is a PP1 inhibition. Ser48 and Ser67 are 
dephosphorylated by the serine/threonine protein phospha­
tases type 2A and 2B (PP2A and PP2B). PP2B is a Ca2+ – 
calmodulin dependent enzyme, also named calcineurin [45]. 
Furthermore, PP1 is regulated by two heat and acid-stable 
proteins, inhibitor 1 (INH-1) and INH-2. INH-1 becomes 
active upon phosphorylation on Thr35 site by PKA [45,46]. 
In turn, the INH-1 is also dephosphorylated by PP2A and 
PP2B [45]. As stated above, PKA, through the phosphor­
ylation of PP1 and of the INH-1 and the consequent 
inhibition of PP1, amplifies its own signal (PKA-dependent
PLN. PP1Fig. 2. Regulation of the phosphatase that dephosphorylates 
consists of a catalytic subunit (PP1C) and a regulatory protein that targets the 
enzyme to the SR (PP1GM). PP1GM can be phosphorylated at Ser48 and 
Ser67. Phosphorylation of Ser67 disrupts the interaction PP1C – PP1GM, and 
the catalytic subunit released is less active towards PLN. In contrast, Ser48 
phosphorylation increases PP1 activity. PKA phosphorylates both sites being 
the net effect, inhibition of PP1 activity. SR-bound CaMKII phosphorylates 
only the Ser48 site. Dephosphorylation of both sites on PP1GM is 
acomplished by PP2A and PP2B. PP1 activity is also regulated by accessory 
proteins, the inhibitor 1 and 2 (INH-1 and INH-2). PKA phosphorylation of 
Thr35 of INH-1 turns on its inhibitory activity towards PP1. Phosphorylation 
of Ser67 of INH-1 by the Ca2+- and phospholipid-dependent PKCa increases 
the activity of PP1. Dephosphorylation of INH-1 is carried out by PP2A and 
PP2B. Open arrows indicate the points of Ca2+ regulation.
Ser16 phosphorylation) and unmasks the CaMKII-dependent 
phosphorylation of Thr17 (Fig. 1). The increase in Ca2+, on 
the other hand, is a potential mechanism by which these 
signals may be damped. It was shown that the increase in 
extracellular Ca2+ in the presence of isoproterenol produced 
a further increase in the phosphorylation of Thr17 of PLN, 
which is associated with a significant decrease in the 
phosphorylation of Ser16 residue [47]. One possible explan­
ation for this finding might lie in the subtle interaction 
between the different players intervening in the phosphor­
ylation of PLN (Figs. 1 and 2): the increase in Ca2+ by 
activating PP2B may dephosphorylate the INH-1 and PP1. 
Both dephosphorylations would enhance PP1 activity, 
overriding the inhibitory effect of PKA on this phosphatase. 
Activation of PP1 through this cascade might be responsible 
for the decrease in the phosphorylation of Ser16 residue of 
PLN, observed in the presence of isoproterenol and high 
Ca2+. In line with this idea, recent experiments demonstrated 
that the phosphorylation of the INH-1 at Ser67 (a site 
different from that phosphorylated by PKA), by the Ca2+- 
and phospholipid-dependent PKCa, increased PP1 activity 
and decreased Ser16 phosphorylation of PLN [48]. Finally, 
Ser48 of PP1GM is phosphorylated by CaMKII in the striated 
skeletal muscle [49]. If this mechanism is also active in 
cardiac muscle, it would directly contribute to PP1 
activation. Obviously, PP1 activation would not only affect 
the phosphorylation of Ser16 of PLN but also limit the 
CaMKII-dependent increase in Thr17 phosphorylation. 
Overall, different types of evidence indicate that this 
phosphatase regulatory cascade may constitute a fine 
mechanism by which the increase in Ca2+ attenuates the 
signals that act via cAMP. This cascade would also damp the 
phosphorylations produced by sustained increases in Ca2+.
3. Phosphorylation of Thr17 of PLN in pathological 
conditions
3.1. Acidosis
It has been known for over a century that intracellular 
acidosis is associated with a decrease in the ability of the heart 
to generate tension [50]. Acidosis produces a rapid decrease 
in the contraction, which is largely due to a decrease in 
myofilament Ca2+ responsiveness [51]. The decrease in 
contractility is associated with an impairment of relaxation, 
which occurs in spite of the decrease in the responsiveness of 
the contractile proteins and appears to be mainly produced by 
a direct inhibition of SERCA2a [52]. This initial impairment 
of contractility and relaxation is followed by a spontaneous 
mechanical recovery which requires an intact SR and has 
been shown to be dependent on the activity of the CaMKII. 
Experiments by DeSantiago et al. [53] showed that this 
recovery did not occur in hearts of PLN-KO mice. These 
experiments first suggested an important role of the 
phosphorylation of PLN, particularly the Thr17 residue, in 
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the recovery from acidosis. This suggestion was based on 
earlier experiments showing that the simultaneous increase in 
intracellular Ca2+ and the acidosis-induced inhibition of 
phosphatases produces an increase in the phosphorylation of 
Thr17 [47]. Recent experiments showed that phosphorylation 
of Thr17 site of PLN transiently increased at the onset of 
acidosis and is associated with a great part to the contractile 
and relaxation recoveries that follow the acidotic insult, most 
of which occurred within the first 3 min of acidosis [54]. This 
phosphorylation would provide a mechanism to overcome 
the direct depressant effect of acidosis on SERCA2a [52]. A 
more prominent role of the phosphorylation of PLN residues 
might be expected in vivo. Systemic acidosis is known to 
increase sympathetic nerve activity [55]. This increased 
sympathetic tone may produce a more persistent phosphor­
ylation of both, Thr17 and Ser16, residues of PLN, with a 
further contribution to the mechanical recovery. Finally, the 
experiments by DeSantiago et al. [53], showing the absence 
of mechanical recovery of myocytes lacking PLN, would 
indicate that the presence of PLN, as opposite to the chronic 
de-repression of SERCA2a in PLN-KO mice, may be 
required throughout the entire acidosis period for both the 
relaxation and contractile recoveries.
3.2. Stunning
Myocardial stunning describes the reversible decrease in 
myocardial contractility that follows a brief ischemic insult, 
clinically manifested as sluggish recovery of the pump 
function after revascularization [56]. The relevant character­
istic of this phenomenon is the reversible nature of the 
process, in contrast with the irreversible myocardial dysfunc­
tion that occurs with the presence of necrosis or apoptosis. 
The mechanisms responsible for the delayed recovery of 
contractile function are not completely clear [57]. Different 
types of evidence in rodents and human indicate that the 
ultimate cause of the alteration of myocardial contractility 
was a decrease in myofilament Ca2+ responsiveness, since the 
Ca2+ transient was not altered, although contractility was 
decreased. Although the results are not unanimous, this 
decrease in myofilament Ca2+ responsiveness was attributed, 
at least in rodents, to the degradation of TnI [58]. On the other 
hand, experimental evidence indicates that the function of the 
SR is altered, both in the reversible as well as in the 
irreversible ischemia–reperfusion injury [59 – 63]. In partic­
ular, in the case of myocardial stunning, a decrease in the 
activity of SERCA2a and/or in the rate of Ca2+ reuptake by 
the SR has been described in several species, including rats, 
mice, dogs and humans, submitted to moderate and reversible 
injury during cardiac surgery [60 – 62]. An intriguing ques­
tion is, therefore, why does the intracellular Ca2+ transient 
remain unaltered in species in which the SR function is 
depressed? A possible explanation to this puzzle is that 
compensatory mechanisms can overcome the depressed 
SERCA2a activity. Experiments in perfused rat hearts 
demonstrated an increase in the phosphorylation of Thr17 
residue of PLN at the beginning of reperfusion (1– 3 min), 
which was decreased to basal levels by the inhibitor of the 
reverse mode of the NCX, KB-R7943. The decrease of this 
phosphorylation by CaMKII inhibition prolonged half 
relaxation time, which indicates that the phosphorylation 
of Thr17, when present, attenuates the impaired relaxation 
that occurs at the beginning of reperfusion [64]. Further­
more, in transgenic mice in which Thr17 of PLN was 
mutated to Ala, the contractile recovery after an ischemic 
period was significantly diminished and relaxation was 
prolonged when compared to the recovery of mice with 
intact PLN [65]. These results indicate that phosphorylation 
of Thr17, although transient, may play a significant role in 
the critical phase of initial reperfusion, favoring Ca2+ re­
uptake by the SR. This would tend to compensate the 
depression of SERCA2a and would ameliorate Ca2+ over­
load, typical of the beginning of reflow [57]. Moreover, 
these experiments indicate that activation of SERCA2a by 
any other means, at this crucial moment of reperfusion, may 
greatly contribute to Ca2+ handling. In accordance to this 
view, recent experiments suggested that the cardioprotection 
produced by cGMP-mediated stimuli in reoxygenated cells 
is associated with an increase in the phosphorylation of 
Ser16 of PLN [66]. Fig. 3 is a scheme showing the possible 
cascade of events, leading to the phosphorylation of Thr17 at 
the beginning of reperfusion, and the hypothetical protective 
effect of PLN phosphorylation on stunning.
Longer periods of ischemia may lead, to a different PLN 
phosphorylation pattern [63,67]. In hearts submitted to 30 
min of ischemia followed by reperfusion, Xie et al. [67] 
showed that phosphorylation of Thr17 significantly 
decreased at the end of ischemia and at the beginning of 
reperfusion, when phosphorylation of Ser16 was enhanced. 
Interestingly, these authors described that intermittent 
hypoxia protects against the ischemia/reperfusion injury by 
increasing both Ser16 and Thr17 phosphorylation, supporting 
the concept that phosphorylation of both residues is 
important for myocardial recovery after the ischemic period.
Finally, Kim et al. [68] described that in large animals 
whose contractility is more dependent on extracellular Ca2+, 
an alteration of Ca2+ handling is the main cause of stunning, 
instead of the decrease in Ca2+ responsiveness of the 
myofilaments, observed in rodents. In association with the 
altered Ca2+ handling, the authors described a dephosphor­
ylation of Ser16 site of PLN at the end of reperfusion and 
speculated that these alterations might constitute the cellular 
basis of stunning in large mammals. In these large animals, 
it would be interesting to examine the status of Thr17 
phosphorylation all along the reperfusion period and 
particularly in the crucial first minutes of reflow.
3.3. Heart failure
Heart failure (HF) develops when the heart is unable to 
provide an adequate cardiac output to meet the metabolic 
needs of the organism. Substantial progress has been made
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Fig. 3. Cascade of events leading to the generation of stunning and the 
putative protective role of PLN. The accumulation of protons during 
ischemia activates the Na+/H+exchanger (NHE) to extrude H+, with the 
consequent increase in intracellular Na+. The increase in intracellular Na+ 
favors the reverse mode of the Na+/Ca2+ exchanger (NCX) that as a 
counterpart of Na+ extrusion promotes Ca2+ influx, leading to Ca2+ 
overload. The increase in intracellular Ca2+ activates Ca2+-dependent 
proteases, such as calpains that has been proposed to be responsible for the 
proteolysis of different proteins, like myofilament proteins, the suggested 
endpoint of myocardial stunning in rodents. The phosphorylation of PLN at 
Thr17 through CaMKII, and at Ser16 by PKG, by increasing SR Ca2+ 
uptake, could limit the Ca2+ overload.
over the past few years in elucidating the pathophysiology of 
contractile dysfunction and its various subcellular molecular 
counterparts. There is evidence supporting a decrease in 
intracellular Ca2+ transient and a diminished SR Ca2+ load, 
as a central feature in the altered contractility of the failing 
heart [69,70]. These abnormalities in intracellular Ca2+ have 
been associated in most of HF models, with alterations in the 
expression and/or activity of different Ca2+ regulatory 
proteins, particularly, a decrease in SERCA2a expression 
and an increase in NCX expression [71]. An increased Ca2+ 
leak, through hyperphosphorylated RyR2, would also con­
tribute to the decrease in SR Ca2+ content and Ca2+ release, 
typical of HF [72]. Consistently with the decrease in 
SERCA2a expression, several studies indicated that SER- 
CA2a activity and/or SR Ca2+ uptake are impaired in the 
failing heart [71]. The decrease in SERCA2a expression is 
associated with either a smaller decrease or no change in 
PLN expression, which results in a decrease in the ratio 
SERCA2a/PLN and a further decrease in SR Ca2+ uptake. In 
this scenario, the level of phosphorylation of PLN becomes a 
crucial factor which, unfortunately, has not been well defined 
either in hypertrophy or HF. Phosphorylation of PLN has 
been found to be decreased by some authors, either at Ser16 
[73,74], Thr17 [75,76] or both [77]. This should be consistent 
with the h-adrenergic down-regulation and the increase in 
PP1 activity, described in some HF models [78,79]. The 
decrease in the phosphorylation of PLN would be detrimen­
tal, since it would add to the decrease in SERCA2a / PLN 
ratio, to further inhibit SERCA2a activity. Other studies have 
observed, however, either no changes at the Ser16 site [75], 
or even an increase in total PLN phosphorylation [80]. The 
cause for these contradictory results may lay in the different 
HF models and the different times at which the phosphor­
ylation of PLN was studied in the development of HF. 
Referent in particular to the phosphorylation of Thr17 site, 
numerous studies indicate that elevation of intracellular Ca2+ 
is implicated in cardiac hypertrophic signaling [81]. This 
elevated Ca2+ may not only activate the pathway that 
produces the hypertrophic signals, but may also modify 
phosphorylation pathways of proteins involved in the 
excitation – contraction-coupling, through the activation of 
Ca2+-dependent kinases, among which Thr17 of PLN is a 
possible candidate. However, and as stated above, the 
increase in Ca2+ might also trigger the activation of 
phosphatases and lead to a depressed CaMKII activity and 
diminished Thr17 phosphorylation [36,45]. Indeed, although 
in some HF models, CaMKII activity and expression have 
been reported to be decreased [75,76], these were found to be 
increased in others, like human HF with dilated cardiomy­
opathy [82,83]. It would be important to know the time 
course of the phosphorylation of Thr17 of PLN (as well as of 
the other CaMKII-dependent phosphorylations), and the 
consequences of this putative phosphorylation in the 
transition and progression from hypertrophy to HF. Of 
particular interest is the fact that experiments in transgenic 
mice in which PLN was overexpressed, a feedback loop was 
described between the proximal and distal ends of the h- 
adrenergic pathway [84]. According to these results, an 
increase in PLN expression or function would lead to an 
increase in h-adrenergic activity, to phosphorylate PLN and 
therefore maintain cardiac function. Moreover, if PLN 
phosphorylation decreased, as in some HF models, adrener­
gic activity would increase to maintain cardiac function. As 
sustained increases in cardiac adrenergic activity are 
detrimental to the heart [84], pharmacological tools that 
selectively increase PLN phosphorylation might turn to be 
beneficial in the evolution to HF.
4. Conclusions and perspectives
Taken together, these findings suggest that the Thr17 site 
in PLN is phosphorylated under conditions of h-adreno- 
ceptor stimulation and contributes to the relaxant effect of 
the high concentrations of the h-agonists. Moreover,
A. Mattiazzi et al. / Cardiovascular Research 68 (2005) 366 – 375 373
evidence was presented indicating that the phosphorylation 
of this residue is also implicated in the mechanical recovery 
under some pathological conditions, like acidosis and 
stunning. An interesting point is that although the phos­
phorylation experiments reveal that the phosphorylation of 
Thr17 is transient — albeit prominent — and occurs only at 
the beginning of both acidosis and reperfusion, the presence 
of this residue (and/or that of intact PLN), seems to be 
necessary for the mechanical recovery all along the 
reperfusion or acidotic period. These results, together with 
the fact that phosphorylation of Ser16 of PLN by cGMP has 
been also shown to be protective in ischemia/reperfusion 
injury, shed new lights for the search of novel strategies for 
cardioprotection in the clinical setting. Moreover, it is 
important to examine whether the increase in Ca2+, involved 
in the genesis of myocardial hypertrophy, may increase 
CaMKII activity and therefore the phosphorylation of Thr17 
of PLN, and whether this increased PLN-phosphorylation 
may influence the evolution from hypertrophy to HF.
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